Transcatheter Aortic Valve Implantation in Patients With Advanced Chronic Kidney Disease

Federico Conrotto, Stefano Salizzoni, Alessandro Andreis, Fabrizio D'Ascenzo, Augusto D'Onofrio, Marco Agrifoglio, Alaide Chieffo, Antonio Colombo, Filippo Rapetto, Francesco Santini, Giuseppe Tarantini, Davide Gabbieri, Carlo Savini, Sebastiano Immè, Flavio Ribichini, Orazio Valsecchi, Marco Aiello, Giovanni Lixi, Alessandro Iadanza, Esmeralda PompeiMiroslava Stolcova, Diego Ornaghi, Alessandro Minati, Mauro Cassese, Gian Luca Martinelli, Pierluigi Sbarra, Andrea Agostinelli, Andrea Audo, Andrea Pieroni, Rosario Fiorilli, Gino Gerosa, Mauro Rinaldi, Fiorenzo Gaita

Research output: Contribution to journalArticle

Abstract

Advanced chronic kidney disease (CKD) is associated with poor outcomes in patients who underwent surgical aortic valve replacement, whereas its prognostic role in transcatheter aortic valve implantation (TAVI) remains unclear. This study aimed to investigate outcomes in patients with advanced CKD who underwent TAVI. A total of 1,904 consecutive patients who underwent balloon-expandable TAVI in 33 centers between 2007 and 2012 were enrolled in the Italian Transcatheter Balloon-Expandable Valve Implantation Registry. Advanced CKD was defined according to the estimated glomerular filtration rate: 15 to 29 ml/min/1.73 m2 stage 4 (S4), <15 ml/min/1.73 m2 stage 5 (S5). Edwards Sapien or Sapien-XT prosthesis were used. The primary end point was all-cause mortality during follow-up. Secondary end points were major adverse cardiac events at 30 days and at follow-up, defined with Valve Academic Research Consortium 2 criteria. A total of 421 patients were staged S5 (n = 74) or S4 (n = 347). S5 patients were younger and had more frequently porcelain aorta and a lower incidence of previous stroke. Periprocedural and 30-day outcomes were similar in S5 and S4 patients. During 670 (±466) days of follow-up, S5 patients had higher mortality rates (69% vs 39%, p <0.01) and cardiac death (19% vs 9%, p = 0.02) compared with S4 patients. Male gender (hazard ratio [HR] 1.6, 95% confidence interval [CI] 1.2 to 2.2), left ventricular ejection fraction <30% (HR 2.3, 95% CI 1.3 to 4), atrial fibrillation (HR 1.4, 95% CI 1.0 to 1.9), and S5 CKD (HR 1.5, 95% CI 1.0 to 2.1) were independent predictors of death. In conclusion, TAVI in predialytic or dialytic patients (i.e., S5) is independently associated with poor outcomes with more than double risk of death compared with patients with S4 renal function. Conversely, in severe CKD (i.e., S4) a rigorous risk stratification is required to avoid the risk of futility risk.

Original languageEnglish
Pages (from-to)1438-1442
Number of pages5
JournalAmerican Journal of Cardiology
Volume119
Issue number9
DOIs
Publication statusPublished - May 1 2017

Fingerprint

Chronic Renal Insufficiency
Confidence Intervals
Transcatheter Aortic Valve Replacement
Medical Futility
Dental Porcelain
Mortality
Glomerular Filtration Rate
Aortic Valve
Surgical Instruments
Stroke Volume
Atrial Fibrillation
Prostheses and Implants
Registries
Aorta
Stroke
Kidney
Incidence

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Transcatheter Aortic Valve Implantation in Patients With Advanced Chronic Kidney Disease. / Conrotto, Federico; Salizzoni, Stefano; Andreis, Alessandro; D'Ascenzo, Fabrizio; D'Onofrio, Augusto; Agrifoglio, Marco; Chieffo, Alaide; Colombo, Antonio; Rapetto, Filippo; Santini, Francesco; Tarantini, Giuseppe; Gabbieri, Davide; Savini, Carlo; Immè, Sebastiano; Ribichini, Flavio; Valsecchi, Orazio; Aiello, Marco; Lixi, Giovanni; Iadanza, Alessandro; Pompei, Esmeralda; Stolcova, Miroslava; Ornaghi, Diego; Minati, Alessandro; Cassese, Mauro; Martinelli, Gian Luca; Sbarra, Pierluigi; Agostinelli, Andrea; Audo, Andrea; Pieroni, Andrea; Fiorilli, Rosario; Gerosa, Gino; Rinaldi, Mauro; Gaita, Fiorenzo.

In: American Journal of Cardiology, Vol. 119, No. 9, 01.05.2017, p. 1438-1442.

Research output: Contribution to journalArticle

Conrotto, F, Salizzoni, S, Andreis, A, D'Ascenzo, F, D'Onofrio, A, Agrifoglio, M, Chieffo, A, Colombo, A, Rapetto, F, Santini, F, Tarantini, G, Gabbieri, D, Savini, C, Immè, S, Ribichini, F, Valsecchi, O, Aiello, M, Lixi, G, Iadanza, A, Pompei, E, Stolcova, M, Ornaghi, D, Minati, A, Cassese, M, Martinelli, GL, Sbarra, P, Agostinelli, A, Audo, A, Pieroni, A, Fiorilli, R, Gerosa, G, Rinaldi, M & Gaita, F 2017, 'Transcatheter Aortic Valve Implantation in Patients With Advanced Chronic Kidney Disease', American Journal of Cardiology, vol. 119, no. 9, pp. 1438-1442. https://doi.org/10.1016/j.amjcard.2017.01.042
Conrotto, Federico ; Salizzoni, Stefano ; Andreis, Alessandro ; D'Ascenzo, Fabrizio ; D'Onofrio, Augusto ; Agrifoglio, Marco ; Chieffo, Alaide ; Colombo, Antonio ; Rapetto, Filippo ; Santini, Francesco ; Tarantini, Giuseppe ; Gabbieri, Davide ; Savini, Carlo ; Immè, Sebastiano ; Ribichini, Flavio ; Valsecchi, Orazio ; Aiello, Marco ; Lixi, Giovanni ; Iadanza, Alessandro ; Pompei, Esmeralda ; Stolcova, Miroslava ; Ornaghi, Diego ; Minati, Alessandro ; Cassese, Mauro ; Martinelli, Gian Luca ; Sbarra, Pierluigi ; Agostinelli, Andrea ; Audo, Andrea ; Pieroni, Andrea ; Fiorilli, Rosario ; Gerosa, Gino ; Rinaldi, Mauro ; Gaita, Fiorenzo. / Transcatheter Aortic Valve Implantation in Patients With Advanced Chronic Kidney Disease. In: American Journal of Cardiology. 2017 ; Vol. 119, No. 9. pp. 1438-1442.
@article{0f26652f1c814820b2f60fa4997c0ae1,
title = "Transcatheter Aortic Valve Implantation in Patients With Advanced Chronic Kidney Disease",
abstract = "Advanced chronic kidney disease (CKD) is associated with poor outcomes in patients who underwent surgical aortic valve replacement, whereas its prognostic role in transcatheter aortic valve implantation (TAVI) remains unclear. This study aimed to investigate outcomes in patients with advanced CKD who underwent TAVI. A total of 1,904 consecutive patients who underwent balloon-expandable TAVI in 33 centers between 2007 and 2012 were enrolled in the Italian Transcatheter Balloon-Expandable Valve Implantation Registry. Advanced CKD was defined according to the estimated glomerular filtration rate: 15 to 29 ml/min/1.73 m2 stage 4 (S4), <15 ml/min/1.73 m2 stage 5 (S5). Edwards Sapien or Sapien-XT prosthesis were used. The primary end point was all-cause mortality during follow-up. Secondary end points were major adverse cardiac events at 30 days and at follow-up, defined with Valve Academic Research Consortium 2 criteria. A total of 421 patients were staged S5 (n = 74) or S4 (n = 347). S5 patients were younger and had more frequently porcelain aorta and a lower incidence of previous stroke. Periprocedural and 30-day outcomes were similar in S5 and S4 patients. During 670 (±466) days of follow-up, S5 patients had higher mortality rates (69{\%} vs 39{\%}, p <0.01) and cardiac death (19{\%} vs 9{\%}, p = 0.02) compared with S4 patients. Male gender (hazard ratio [HR] 1.6, 95{\%} confidence interval [CI] 1.2 to 2.2), left ventricular ejection fraction <30{\%} (HR 2.3, 95{\%} CI 1.3 to 4), atrial fibrillation (HR 1.4, 95{\%} CI 1.0 to 1.9), and S5 CKD (HR 1.5, 95{\%} CI 1.0 to 2.1) were independent predictors of death. In conclusion, TAVI in predialytic or dialytic patients (i.e., S5) is independently associated with poor outcomes with more than double risk of death compared with patients with S4 renal function. Conversely, in severe CKD (i.e., S4) a rigorous risk stratification is required to avoid the risk of futility risk.",
author = "Federico Conrotto and Stefano Salizzoni and Alessandro Andreis and Fabrizio D'Ascenzo and Augusto D'Onofrio and Marco Agrifoglio and Alaide Chieffo and Antonio Colombo and Filippo Rapetto and Francesco Santini and Giuseppe Tarantini and Davide Gabbieri and Carlo Savini and Sebastiano Imm{\`e} and Flavio Ribichini and Orazio Valsecchi and Marco Aiello and Giovanni Lixi and Alessandro Iadanza and Esmeralda Pompei and Miroslava Stolcova and Diego Ornaghi and Alessandro Minati and Mauro Cassese and Martinelli, {Gian Luca} and Pierluigi Sbarra and Andrea Agostinelli and Andrea Audo and Andrea Pieroni and Rosario Fiorilli and Gino Gerosa and Mauro Rinaldi and Fiorenzo Gaita",
year = "2017",
month = "5",
day = "1",
doi = "10.1016/j.amjcard.2017.01.042",
language = "English",
volume = "119",
pages = "1438--1442",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Transcatheter Aortic Valve Implantation in Patients With Advanced Chronic Kidney Disease

AU - Conrotto, Federico

AU - Salizzoni, Stefano

AU - Andreis, Alessandro

AU - D'Ascenzo, Fabrizio

AU - D'Onofrio, Augusto

AU - Agrifoglio, Marco

AU - Chieffo, Alaide

AU - Colombo, Antonio

AU - Rapetto, Filippo

AU - Santini, Francesco

AU - Tarantini, Giuseppe

AU - Gabbieri, Davide

AU - Savini, Carlo

AU - Immè, Sebastiano

AU - Ribichini, Flavio

AU - Valsecchi, Orazio

AU - Aiello, Marco

AU - Lixi, Giovanni

AU - Iadanza, Alessandro

AU - Pompei, Esmeralda

AU - Stolcova, Miroslava

AU - Ornaghi, Diego

AU - Minati, Alessandro

AU - Cassese, Mauro

AU - Martinelli, Gian Luca

AU - Sbarra, Pierluigi

AU - Agostinelli, Andrea

AU - Audo, Andrea

AU - Pieroni, Andrea

AU - Fiorilli, Rosario

AU - Gerosa, Gino

AU - Rinaldi, Mauro

AU - Gaita, Fiorenzo

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Advanced chronic kidney disease (CKD) is associated with poor outcomes in patients who underwent surgical aortic valve replacement, whereas its prognostic role in transcatheter aortic valve implantation (TAVI) remains unclear. This study aimed to investigate outcomes in patients with advanced CKD who underwent TAVI. A total of 1,904 consecutive patients who underwent balloon-expandable TAVI in 33 centers between 2007 and 2012 were enrolled in the Italian Transcatheter Balloon-Expandable Valve Implantation Registry. Advanced CKD was defined according to the estimated glomerular filtration rate: 15 to 29 ml/min/1.73 m2 stage 4 (S4), <15 ml/min/1.73 m2 stage 5 (S5). Edwards Sapien or Sapien-XT prosthesis were used. The primary end point was all-cause mortality during follow-up. Secondary end points were major adverse cardiac events at 30 days and at follow-up, defined with Valve Academic Research Consortium 2 criteria. A total of 421 patients were staged S5 (n = 74) or S4 (n = 347). S5 patients were younger and had more frequently porcelain aorta and a lower incidence of previous stroke. Periprocedural and 30-day outcomes were similar in S5 and S4 patients. During 670 (±466) days of follow-up, S5 patients had higher mortality rates (69% vs 39%, p <0.01) and cardiac death (19% vs 9%, p = 0.02) compared with S4 patients. Male gender (hazard ratio [HR] 1.6, 95% confidence interval [CI] 1.2 to 2.2), left ventricular ejection fraction <30% (HR 2.3, 95% CI 1.3 to 4), atrial fibrillation (HR 1.4, 95% CI 1.0 to 1.9), and S5 CKD (HR 1.5, 95% CI 1.0 to 2.1) were independent predictors of death. In conclusion, TAVI in predialytic or dialytic patients (i.e., S5) is independently associated with poor outcomes with more than double risk of death compared with patients with S4 renal function. Conversely, in severe CKD (i.e., S4) a rigorous risk stratification is required to avoid the risk of futility risk.

AB - Advanced chronic kidney disease (CKD) is associated with poor outcomes in patients who underwent surgical aortic valve replacement, whereas its prognostic role in transcatheter aortic valve implantation (TAVI) remains unclear. This study aimed to investigate outcomes in patients with advanced CKD who underwent TAVI. A total of 1,904 consecutive patients who underwent balloon-expandable TAVI in 33 centers between 2007 and 2012 were enrolled in the Italian Transcatheter Balloon-Expandable Valve Implantation Registry. Advanced CKD was defined according to the estimated glomerular filtration rate: 15 to 29 ml/min/1.73 m2 stage 4 (S4), <15 ml/min/1.73 m2 stage 5 (S5). Edwards Sapien or Sapien-XT prosthesis were used. The primary end point was all-cause mortality during follow-up. Secondary end points were major adverse cardiac events at 30 days and at follow-up, defined with Valve Academic Research Consortium 2 criteria. A total of 421 patients were staged S5 (n = 74) or S4 (n = 347). S5 patients were younger and had more frequently porcelain aorta and a lower incidence of previous stroke. Periprocedural and 30-day outcomes were similar in S5 and S4 patients. During 670 (±466) days of follow-up, S5 patients had higher mortality rates (69% vs 39%, p <0.01) and cardiac death (19% vs 9%, p = 0.02) compared with S4 patients. Male gender (hazard ratio [HR] 1.6, 95% confidence interval [CI] 1.2 to 2.2), left ventricular ejection fraction <30% (HR 2.3, 95% CI 1.3 to 4), atrial fibrillation (HR 1.4, 95% CI 1.0 to 1.9), and S5 CKD (HR 1.5, 95% CI 1.0 to 2.1) were independent predictors of death. In conclusion, TAVI in predialytic or dialytic patients (i.e., S5) is independently associated with poor outcomes with more than double risk of death compared with patients with S4 renal function. Conversely, in severe CKD (i.e., S4) a rigorous risk stratification is required to avoid the risk of futility risk.

UR - http://www.scopus.com/inward/record.url?scp=85015447270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015447270&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2017.01.042

DO - 10.1016/j.amjcard.2017.01.042

M3 - Article

C2 - 28325569

AN - SCOPUS:85015447270

VL - 119

SP - 1438

EP - 1442

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 9

ER -